Minutes
Animal plasma clearance is rapid after studied IM/IV routes; this does not define effect duration in humans.
Protocol / Research Dosing Guide
BPC-157 Dosage Guide: Research Evidence, Reconstitution and Safety
An evidence-organized BPC-157 reference separating animal protocols, very limited human reports, and community dosing claims.
Last reviewed September 15, 202621 minute readResearch information only
Level 2 — Primarily preclinicalVery limited human reportsNot FDA approved
BPC-157 Quick Start
BPC-157 is a synthetic pentadecapeptide studied mainly in laboratory and animal models. Human evidence is limited to very small reports and does not establish a subcutaneous or oral regimen, efficacy, or long-term safety.
Why researchers care
Gastrointestinal and tissue-repair research
Class
Synthetic 15-amino-acid peptide
Route reported
Multiple animal routes; limited human IV and intra-articular reports
Cycle length
Community cycles reported; not validated
Regulatory status
Not FDA approved; WADA prohibited
Loading supplier information
BPC-157 Dosing Protocol and Schedule
The supplied source reports subcutaneous and oral community ranges. These are not human dose-finding results. The only published human IV pilot involved two participants and cannot validate community schedules or other routes.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Community low | 250 mcg | Once daily; not clinically validated |
| Community standard | 250 mcg | Twice daily; not clinically validated |
| Community high | 500 mcg | Twice daily; not clinically validated |
| Human IV pilot | 10 mg or 20 mg | Single infusion in two participants; study parameter only |
No Phase 2 or Phase 3 dose-finding trial establishes a human BPC-157 regimen, cycle, taper, or rest period.
BPC-157 Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
BPC-157 Reconstitution Calculator
Vial-format concentration math
Concentration
5 mg/mL
Draw volume
0.05 mL
U-100 units
5
Mathematical draws
40
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take BPC-157: Morning or Night?
Morning or evening?
No human study establishes a preferred time.
Once or twice daily?
Both are community patterns, not validated frequencies.
With food?
Oral community timing is not supported by human exposure data.
Missed amount?
No validated replacement or doubling instructions exist.
BPC-157 Route Comparison
| Route | Research context | Evidence limit |
|---|---|---|
| Oral, IV, IM, and SC | Rat and dog pharmacokinetic study | Animal data only |
| Intravenous | Two-person single-infusion human pilot | Too small for efficacy or dosing |
| Intra-articular | Small human knee-pain case series | Uncontrolled and route-specific |
| Subcutaneous or oral human use | Community reported | No published human dose-finding trial |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
BPC-157 Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Animal plasma half-life | Under 30 minutes reported after IM/IV | Rat and dog data only |
| Human half-life | Not established | No adequate human PK study |
| SC frequency | Community reported | Not derived from human PK |
| Route conversion | Not established | Animal and human routes are not interchangeable |
BPC-157 Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 250 mcg | Once or twice daily | Community report | No |
| Subcutaneous | 500 mcg | Twice daily | Community report | No |
| Oral | 250–500 mcg | Once or twice daily | Community report | No |
| Intravenous | 10 mg or 20 mg | Single infusion | Two-person human pilot | Study design only |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
BPC-157 Reconstitution Guide
Concentration: 2.5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.25 mg | 0.1 mL | 10 units |
| 0.5 mg | 0.2 mL | 20 units |
| 0.75 mg | 0.3 mL | 30 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How BPC-157 Works
Gastric peptide fragment
BPC-157 is a synthetic 15-amino-acid sequence derived from a gastric-protein fragment.
BPC-157 Human Trials and FDA Status
Current status · verified September 15, 2026
Not FDA approved; WADA prohibited
- Most published BPC-157 evidence comes from laboratory and rodent models.
- A two-person 2025 pilot reported single 10 mg and 20 mg IV infusions with limited short-term safety observations.
- A small uncontrolled knee-pain case series used intra-articular injection.
- No Phase 2 or Phase 3 randomized dose-finding trial was identified.
- BPC-157 is not FDA approved and is prohibited under WADA's non-approved substances category.
Who Should Avoid BPC-157?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No human safety data
Children or adolescents
No established pediatric use
Active or recent cancer
Angiogenesis-related uncertainty
Blood-pressure or vascular conditions
Nitric-oxide effects and interactions are unresolved
Tested athletes
WADA prohibits BPC-157
Long-term or repeated use
No adequate human safety data
BPC-157 Side Effects, Risks and Safety
Injection-site irritationAnecdotal
Important limitation: No controlled SC incidence data.
Angiogenesis and cancer riskTheoretical
Important limitation: Long-term human risk is unresolved.
Blood-pressure interactionsTheoretical
Important limitation: No interaction studies.
Reproductive effectsUnknown
Important limitation: No human pregnancy or fertility data.
Product contamination or mislabelingPractical risk
Important limitation: Unapproved research products lack approved-drug controls.
Long-term effectsUnknown
Important limitation: Human follow-up is inadequate.
BPC-157 Timeline and Monitoring
Four to twelve weeks
Community cycle range, not a clinical study standard.
Repeat cycles
No restart interval or cumulative-exposure limit is established.
Monitoring
No validated SC or oral biomarker panel, stopping rule, or follow-up schedule exists.
BPC-157 Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Tendon or ligament healing | Level 2 — preclinical | Rodent studies report repair signals | No controlled human efficacy trial |
| Gastrointestinal protection | Level 2 — preclinical | Extensive animal literature | No established human treatment effect |
| Angiogenesis and vascular repair | Level 2 — preclinical | Animal and cellular mechanisms | Potential benefit and risk remain unresolved |
| Human pain improvement | Very limited | Small uncontrolled intra-articular report | Cannot establish efficacy |
BPC-157 Storage and Handling
Unreconstituted vial
No approved manufacturer stability specification was identified for current research vials.
Prepared vial
Community 2–8°C and three-to-four-week guidance is not compound-specific validated stability evidence.
Oral product
No approved formulation or universal handling standard exists.
Appearance
Cloudiness, discoloration, or particles do not establish sterility or usability.
BPC-157 Troubleshooting
The solution looks abnormal
Stop and seek qualified product guidance; appearance cannot confirm sterility.
The units differ from another chart
Confirm vial mg, liquid mL, entered mg, and U-100 conversion.
Animal and community amounts conflict
Do not convert animal protocols into human amounts.
Oral and SC guidance conflict
No validated route conversion exists.
A scheduled amount is missed
No validated missed-amount procedure exists.
BPC-157 Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| BPC-157 | Synthetic pentadecapeptide | Primarily animal; very limited human reports | Not approved |
| TB-500 | Thymosin-related fragment | Limited and indirect evidence | Not approved |
| BPC+TB (Wolverine) | Vendor-defined blend | No direct blend studies | Not approved |
| ARA-290 | EPO-derived peptide | Early Phase 2 human research | Not approved |
BPC-157 Frequently Asked Questions
What is BPC-157?
A synthetic 15-amino-acid peptide studied mainly in animal models.
Is it FDA approved?
No.
Does it have human research?
Only very small reports; no adequate dose-finding or efficacy trial.
What is its human half-life?
Not established.
Is the community SC schedule validated?
No.
Is oral use validated in humans?
No human oral dose-finding trial was identified.
Can animal doses be converted to human doses?
Not by this page; animal protocols do not establish human use.
Is it allowed in tested sport?
No. WADA lists BPC-157 as a prohibited non-approved substance.
Is a rest period established?
No.
What does the calculator do?
It performs concentration and volume arithmetic only.
Sources and Research
Coverage source
1. BPC-157 protocol coverage source
Coverage source for community schedules; not the primary authority for efficacy.
Open direct sourceAnimal research
2. Pharmacokinetics of BPC157 in rats and dogs
Primary animal PK across oral, IV, IM, and SC routes.
Open direct sourceHuman research
3. Safety of intravenous BPC157 in humans
Two-person single-infusion pilot; too small to establish efficacy or general dosing.
Open direct sourceRegulatory
4. FDA compounding safety-risk information
Official regulatory context for BPC-157 bulk substance concerns.
Open direct sourceMissing information flagged for review
- Human dose-response and optimal dose: Not established
- Human SC and oral pharmacokinetics: Not established
- Human half-life: Not established
- Phase 2 or Phase 3 efficacy: Not established
- Validated cycle and rest period: Not established
- Approved-product stability: Not established
- Long-term human safety: Not established
- Reproductive safety and drug interactions: Not established